This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Aldose Reductase
From Proteopedia
(Difference between revisions)
| Line 33: | Line 33: | ||
**[[2bgq]] – bAldR - barley<br /> | **[[2bgq]] – bAldR - barley<br /> | ||
**[[2bgs]] - bAldR+NADP<br /> | **[[2bgs]] - bAldR+NADP<br /> | ||
| + | **[[5jh1]] – maAldR – maize<br /> | ||
*Aldose Reductase+inhibitors | *Aldose Reductase+inhibitors | ||
| - | **[[3ghr]], [[3ghs]], [[3ght]], [[3ghu]], [[2r24]], [[2pzn]], [[3g5e]], [[2qxw]], [[2iki]], [[2i16]], [[2i17]], [[1t40]], [[1t41]], [[1us0]], [[1el3]], [[3t42]] - hAldR +NADP+IDD inhibitors<br /> | + | **[[3ghr]], [[3ghs]], [[3ght]], [[3ghu]], [[2r24]], [[2pzn]], [[3g5e]], [[2qxw]], [[2iki]], [[2i16]], [[2i17]], [[1t40]], [[1t41]], [[1us0]], [[1el3]], [[3t42]], [[4ys1]], [[4rpq]], [[4qr6]], [[4qbx]], [[4q7b]], [[2pev]], [[2pf8]], [[2pfh]], [[4puw]], [[4puu]] - hAldR +NADP+IDD inhibitors<br /> |
| - | **[[3onb]], [[3onc]] – hAldR (mutant) +NADP+IDD inhibitor<br /> | + | **[[3onb]], [[3onc]], [[2pdk]], [[1az1]] – hAldR (mutant) +NADP+IDD inhibitor<br /> |
**[[3u2c]] - hAldR +NADP+ NSAID inhibitor<br /> | **[[3u2c]] - hAldR +NADP+ NSAID inhibitor<br /> | ||
**[[3bcj]], [[1x97]], [[1x98]], [[1pwm]], [[1ef3]], [[2pd5]], [[2dux]], [[2duz]], [[2dv0]], [[2fz8]], [[2fz9]], [[2hv5]], [[2hvn]], [[2hvo]], [[1mar]], [[2fzb]], [[2fzd]], [[1z3n]], [[1pwl]], [[1iei]], [[4jir]] - hAldR+NADP+inhibitor for diabetic treatment<br /> | **[[3bcj]], [[1x97]], [[1x98]], [[1pwm]], [[1ef3]], [[2pd5]], [[2dux]], [[2duz]], [[2dv0]], [[2fz8]], [[2fz9]], [[2hv5]], [[2hvn]], [[2hvo]], [[1mar]], [[2fzb]], [[2fzd]], [[1z3n]], [[1pwl]], [[1iei]], [[4jir]] - hAldR+NADP+inhibitor for diabetic treatment<br /> | ||
**[[1z89]], [[1z8a]] - hAldR+NADP+sulfonyl-pyridazinone<br /> | **[[1z89]], [[1z8a]] - hAldR+NADP+sulfonyl-pyridazinone<br /> | ||
| - | **[[2pdg]], [[2pdh]] - hAldR+NADP+uracil inhibitor<br /> | + | **[[5ha7]] – hAldR (mutant) +NADP+pyrimidine inhibitor<br /> |
| + | **[[4yu1]], [[4prt]], [[4prr]], [[4pr4]], [[4nkc]] – hAldR +NADP+ diphenyl inhibitor<br /> | ||
| + | **[[2pdg]], [[2pdh]], [[4xzi]], [[4xzh]] - hAldR+NADP+uracil inhibitor<br /> | ||
**[[1x96]], [[2acs]], [[2acu]] - hAldR+NADP+citrate<br /> | **[[1x96]], [[2acs]], [[2acu]] - hAldR+NADP+citrate<br /> | ||
**[[2acq]] - hAldR +NADP+glucose phosphate<br /> | **[[2acq]] - hAldR +NADP+glucose phosphate<br /> | ||
| Line 49: | Line 52: | ||
**[[2nvc]], [[2nvd]] - hAldR+NADP+isothiazole inhibitor<br /> | **[[2nvc]], [[2nvd]] - hAldR+NADP+isothiazole inhibitor<br /> | ||
**[[3p2v]] - hAldR+NADP+ benzothiazepine inhibitor<br /> | **[[3p2v]] - hAldR+NADP+ benzothiazepine inhibitor<br /> | ||
| - | **[[2pev]], [[2pf8]], [[2pfh]] - hAldR+NADP+IDD inhibitor+ fidarestat<br /> | ||
**[[2ipw]], [[2iq0]], [[2iqd]], [[2isf]], [[2ine]], [[2inz]], [[2is7]] - hAldR+NADP+ acid<br /> | **[[2ipw]], [[2iq0]], [[2iqd]], [[2isf]], [[2ine]], [[2inz]], [[2is7]] - hAldR+NADP+ acid<br /> | ||
**[[2f2k]] - hAldR+NADP+DEG<br /> | **[[2f2k]] - hAldR+NADP+DEG<br /> | ||
**[[2pdn]], [[2pdq]] – hAldR (mutant)+NADP+uracil inhibitor<br /> | **[[2pdn]], [[2pdq]] – hAldR (mutant)+NADP+uracil inhibitor<br /> | ||
**[[2pdb]], [[2pdf]], [[2pdi]], [[2pdm]], [[2pdx]], [[3len]], [[3m0i]], [[3mb9]], [[2pd9]], [[2pdw]], [[2pdy]], [[2agt]], [[2pdl]] – hAldR (mutant)+NADP+inhibitor for diabetic treatment<br /> | **[[2pdb]], [[2pdf]], [[2pdi]], [[2pdm]], [[2pdx]], [[3len]], [[3m0i]], [[3mb9]], [[2pd9]], [[2pdw]], [[2pdy]], [[2agt]], [[2pdl]] – hAldR (mutant)+NADP+inhibitor for diabetic treatment<br /> | ||
| - | **[[2pdk]] - hAldR (mutant)+NADP+sorbinil<br /> | ||
| - | **[[1az1]] – hAldR (mutant)+NADP+alrestatin<br /> | ||
**[[1az2]] - hAldR (mutant)+NADP+citrate<br /> | **[[1az2]] - hAldR (mutant)+NADP+citrate<br /> | ||
**[[3lbo]], [[3ld5]], [[3lql]], [[3lz5]], [[2pdc]], [[3lep]], [[3lqg]], [[3lz3]], [[3m4h]], [[2pdj]], [[2pdp]], [[2pdu]], [[3m64]], [[3mc5]] - hAldR (mutant)+IDD inhibitors<br /> | **[[3lbo]], [[3ld5]], [[3lql]], [[3lz5]], [[2pdc]], [[3lep]], [[3lqg]], [[3lz3]], [[3m4h]], [[2pdj]], [[2pdp]], [[2pdu]], [[3m64]], [[3mc5]] - hAldR (mutant)+IDD inhibitors<br /> | ||
| Line 61: | Line 61: | ||
**[[3rx2]], [[3rx3]], [[3rx4]], [[3s3g]] - hAldR+NADP+ sulindac inhibitor<br /> | **[[3rx2]], [[3rx3]], [[3rx4]], [[3s3g]] - hAldR+NADP+ sulindac inhibitor<br /> | ||
**[[4igs]] - hAldR+NADP+ polyfluorinated inhibitor<br /> | **[[4igs]] - hAldR+NADP+ polyfluorinated inhibitor<br /> | ||
| - | **[[4lau]], [[4laz]], [[4lb3]], [[4lb4]], [[4lbr]], [[4lbs]] - hAldR+NADP+ carbamoyl inhibitor<br /> | + | **[[4lau]], [[4laz]], [[4lb3]], [[4lb4]], [[4lbr]], [[4lbs]], [[4qxi]] - hAldR+NADP+ carbamoyl inhibitor<br /> |
| + | **[[4qx4]] - hAldR+NADP+ mercaptotriazinoindole inhibitor<br /> | ||
**[[3fx4]] – pAldR+NADP+thiazolidine derivative <br /> | **[[3fx4]] – pAldR+NADP+thiazolidine derivative <br /> | ||
| - | **[[ | + | **[[1eko]], [[1ah0]], [[3h4g]], [[1ah3]], [[1ae4]] - pAldR+NADP+IDD inhibitor<br /> |
| - | + | ||
| - | + | ||
| - | + | ||
**[[2vdg]] – bAldR+NADP+butanol <br /> | **[[2vdg]] – bAldR+NADP+butanol <br /> | ||
| + | **[[5jh2]] – maAldR + adenosine diphosphate <br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 09:20, 1 March 2017
| |||||||||||
3D Structures of Aldose Reductase
Updated on 01-March-2017
References
- ↑ Rondeau JM, Tete-Favier F, Podjarny A, Reymann JM, Barth P, Biellmann JF, Moras D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature. 1992 Jan 30;355(6359):469-72. PMID:1734286 doi:http://dx.doi.org/10.1038/355469a0
- ↑ Wilson DK, Bohren KM, Gabbay KH, Quiocho FA. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 1992 Jul 3;257(5066):81-4. PMID:1621098
